The objective of this study is to demonstrate consistency in data between when patients with ROS1-positive NSCLC are identified via liquid biopsies and when they are identified via tissue-based testing (integrated analysis of entrectinib; data cutoff 1 May 2019). Here, ROS1 is linked to non-small cell lung carcinoma.